Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis
Authors:
- Asad Izziddin DajaniADAsad Izziddin Dajani
- Branko PopovicBPBranko Popovic
Open Access
- 6 November 2020
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 8 (21) , 5235-5249
Abstract
Essential phospholipids (EPL) are used for the supportive treatment of non-alcoholic fatty liver disease (NAFLD), but data are mostly from small-scale studies. To evaluate the efficacy of EPL treatment in adult patients with NAFLD and type 2 diabetes and/or obesity. The MEDLINE, PubMed, Embase, and Cochrane databases were searched up to March 2019 for clinical trials and comparative observational studies. Eligible studies were those published in English or Chinese that enrolled adult patients (≥ 18 years) with NAFLD and type 2 diabetes mellitus and/or obesity receiving EPL as monotherapy or as add-on therapy to existing therapy, and that included at least one of the efficacy outcomes of interest. A variety of studies were identified; thus, direct, indirect and cohort meta-analyses were performed. Mean difference (MD) and 95% confidence interval (CI) were calculated for continuous variables, and relative risk with 95%CI for disease response and recovery. A random-effects model was used to address between-study heterogeneity. Ten studies met the inclusion criteria (n = 22-324). EPL treatment duration ranged from 4 to 72 wk. In the direct meta-analysis (four randomized controlled trials), compared with antidiabetic therapy alone, EPL plus antidiabetic therapy was associated with a significantly greater reduction in [alanine aminotransferase (ALT); MD: 11.28 U/L (95%CI: -17.33, -5.23), P = 0.0003], triglyceride [MD: -49.33 mg/dL (95%CI: -66.43, -32.23), P < 0.0001] and total cholesterol levels [MD: -29.74 mg/dL (95%CI: -38.02, -21.45), P < 0.0001]. There was also a significant increase in the rate of overall improvement [relative risk 1.50 (95%CI: 1.26-1.79), P < 0.0001], and risk of no disease (P = 0.0091), and a reduction in moderate disease (P = 0.0187); there were no significant differences in severe disease, mild disease, or significant improvement. In the cohort meta-analysis of three non-randomized clinical trials, the MD in ALT levels was -16.71 U/L (95%CI: -24.94, -8.49) and 23% of patients had improved disease. In the cohort meta-analysis of five randomized trials, MD in ALT levels was –28.53 U/L (95%CI: -35.42, -21.65), and 87% (95%CI: 81%, 93%) and 58% (95%CI: 46%, 70%) of patients showed clinical improvement and significant clinical improvement. This analysis provides evidence for a benefit of EPL in patients with NAFLD and diabetes and/or obesity. Further large-scale trials are warranted.Keywords
This publication has 30 references indexed in Scilit:
- 1366 BENEFICIAL INFLUENCE OF POLYUNSATURATED PHOSPHATIDYLCHOLINE ENHANCES FUNCTIONAL LIVER CONDITION AND LIVER STRUCTURE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS. RESULTS OF PROLONGED RANDOMIZED BLINDED PROSPECTIVE CLINICAL STUDYJournal of Hepatology, 2013
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Endpoints and clinical trial design for nonalcoholic steatohepatitisHepatology, 2011
- Liver biopsy for histological assessment - the case againstSaudi Journal of Gastroenterology, 2010
- Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stressJournal of Hepatology, 2009
- A lipidomic analysis of nonalcoholic fatty liver diseaseHepatology, 2007
- Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic PatientsDiabetes Care, 2007
- The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver DiseaseAnnals of Internal Medicine, 2005
- Effect of essentiale in diabetic subjects with Non - Alcoholic fatty liverInternational Journal of Diabetes in Developing Countries, 2005